Geron Corporation (NasdaqGS: GERN)
Health Care · Biotechnology · US
$1.22
+1.67% today · -11.6% 1Y
Geron Corporation (NasdaqGS: GERN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $783.82M and employs 258 people.
Over the last twelve months the share price has lost 11.6%, trading between 1.04 and 2.01.
Tweenvest scores Geron Corporation across four factors: quality 37/100, value 70/100, growth 100/100. Its strongest factor is growth.
GERN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $783.82M
- Revenue (TTM)
- $204.56M
- P/E
- —
- EPS
- -0.10
- Dividend yield
- —
- Beta (5Y)
- 0.61
- 52-week high
- $2.01
- 52-week low
- $1.04
- Avg volume (3M)
- —
- Shares outstanding
- 642.47M
- Employees
- 258
- Next earnings
- —
About Geron Corporation
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
- ISIN
- US3741631036
- Founded
- 1990
- Listed since
- Jul 31, 1996
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Sana Biotechnology, Inc.NasdaqGS: SANA | $835.22M | $2.79 | +2.57% |
| Arbutus Biopharma CorporationNasdaqGS: ABUS | $827.00M | $4.18 | -2.56% |
| Ardelyx, Inc.NasdaqGM: ARDX | $814.84M | $3.27 | +0.31% |
| Immix Biopharma, Inc.NasdaqCM: IMMX | $802.50M | $9.29 | -4.03% |
| Candel Therapeutics, Inc.NasdaqGM: CADL | $778.96M | $9.66 | -5.11% |
| Annexon, Inc.NasdaqGS: ANNX | $758.32M | $4.00 | -0.25% |
| Getein Biotech, IncSHSE: 603387 | $755.75M | CN¥10.01 | +1.93% |
| Gyre Therapeutics, Inc.NasdaqCM: GYRE | $753.90M | $6.76 | -4.92% |
Figures last refreshed Oct 4, 2026.